[go: up one dir, main page]

MX2025002112A - Composiciones de proteina de fusion recombinante neuregulina-1 (nrg-1) humana y metodos para su uso - Google Patents

Composiciones de proteina de fusion recombinante neuregulina-1 (nrg-1) humana y metodos para su uso

Info

Publication number
MX2025002112A
MX2025002112A MX2025002112A MX2025002112A MX2025002112A MX 2025002112 A MX2025002112 A MX 2025002112A MX 2025002112 A MX2025002112 A MX 2025002112A MX 2025002112 A MX2025002112 A MX 2025002112A MX 2025002112 A MX2025002112 A MX 2025002112A
Authority
MX
Mexico
Prior art keywords
fusion protein
recombinant fusion
nrg
methods
protein compositions
Prior art date
Application number
MX2025002112A
Other languages
English (en)
Inventor
John Li
Shengwei Li
Dixiang Luo
Yiran Wu
Ming Zhou
Xiaolei Zhuang
Liang Hua
Pengyi Luo
Yang Wang
Original Assignee
Salubris Biotherapeutics Inc
Salubris Chengdu Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=66484143&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2025002112(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Salubris Biotherapeutics Inc, Salubris Chengdu Biotech Co Ltd filed Critical Salubris Biotherapeutics Inc
Publication of MX2025002112A publication Critical patent/MX2025002112A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C07K16/1145—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)

Abstract

La presente invención hace referencia a una proteína de fusión recombinante que comprende un fragmento de neuregulina-1 (NRG-1) de proteína cardioprotectora fusionada a una estructura de anticuerpo monoclonal (mAb) y a un método para el tratamiento de una enfermedad o afección en un sujeto que lo necesita que comprende la administración de una cantidad terapéuticamente eficaz de la proteína de fusión recombinante o la composición farmacéutica que comprende la proteína de fusión recombinante descrita en la presente.
MX2025002112A 2018-04-11 2020-10-09 Composiciones de proteina de fusion recombinante neuregulina-1 (nrg-1) humana y metodos para su uso MX2025002112A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862656246P 2018-04-11 2018-04-11
PCT/US2019/026889 WO2019200033A1 (en) 2018-04-11 2019-04-11 Human neuregulin-1 (nrg-1) recombinant fusion protein compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2025002112A true MX2025002112A (es) 2025-05-02

Family

ID=66484143

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020010740A MX2020010740A (es) 2018-04-11 2019-04-11 Composiciones de proteina de fusion recombinante neuregulina-1 (nrg-1) humana y metodos para su uso.
MX2025002112A MX2025002112A (es) 2018-04-11 2020-10-09 Composiciones de proteina de fusion recombinante neuregulina-1 (nrg-1) humana y metodos para su uso

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020010740A MX2020010740A (es) 2018-04-11 2019-04-11 Composiciones de proteina de fusion recombinante neuregulina-1 (nrg-1) humana y metodos para su uso.

Country Status (25)

Country Link
US (3) US11046741B2 (es)
EP (2) EP3774859B1 (es)
JP (3) JP7575272B2 (es)
KR (1) KR20210022542A (es)
CN (2) CN113166218B (es)
AU (2) AU2019252262B2 (es)
BR (1) BR112020020646A2 (es)
CA (1) CA3096420A1 (es)
CL (1) CL2020002621A1 (es)
CO (1) CO2020012621A2 (es)
DK (1) DK3774859T3 (es)
EA (1) EA202092458A1 (es)
ES (1) ES2980163T3 (es)
FI (1) FI3774859T3 (es)
HU (1) HUE066892T2 (es)
IL (2) IL322374A (es)
MX (2) MX2020010740A (es)
MY (1) MY204230A (es)
PE (1) PE20210111A1 (es)
PH (1) PH12020551648A1 (es)
PL (1) PL3774859T3 (es)
PT (1) PT3774859T (es)
SG (1) SG11202009831UA (es)
TW (2) TWI834654B (es)
WO (1) WO2019200033A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210022542A (ko) 2018-04-11 2021-03-03 샐러브리스 바이오테라퓨틱스, 인크. 인간 뉴레귤린-1(nrg-1) 재조합 융합 단백질 조성물 및 이의 사용 방법
AR121035A1 (es) 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso
AU2020348436A1 (en) * 2019-09-16 2022-04-07 Zensun (Shanghai) Science & Technology, Co., Ltd. Recombinant human neuregulin derivatives and use thereof
CN114420310B (zh) * 2022-01-18 2024-11-12 河南大学 基于图转换网络的药物ATC Code预测方法
CA3245956A1 (en) * 2022-03-15 2023-09-21 Salubris Biotherapeutics, Inc. METHODS FOR TREATING FIBROSIS AND ARRHYTHMIA WITH A NEREGULIN-1 FUSION PROTEIN
CN116832040B (zh) * 2023-06-12 2026-01-13 北京市心肺血管疾病研究所 细胞周期蛋白依赖性激酶抑制剂在治疗射血分数保留型心力衰竭中的应用
WO2025122581A1 (en) * 2023-12-08 2025-06-12 The Trustees Of Indiana University Compositions comprising neuregulin and methods of using the same to treat or prevent neurotrophic keratitis
WO2025245112A1 (en) 2024-05-21 2025-11-27 Salubris Biotherapeutics, Inc. Neuregulin-1/anti-her3 antibody fusion protein for use in the treatment of heart failure

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US5834229A (en) 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
IL101943A0 (en) * 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
US5541110A (en) 1994-05-17 1996-07-30 Bristol-Myers Squibb Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
US5912326A (en) 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
AUPP785098A0 (en) * 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
WO2003099320A1 (en) * 2002-05-24 2003-12-04 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
US7994123B2 (en) * 2004-07-09 2011-08-09 Wayne State University Hybrid proteins with ErbB4 extracellular domain and neuregulin heparin-binding domain for targeting
US8142781B2 (en) * 2005-10-07 2012-03-27 Armagen Technologies, Inc. Fusion proteins for blood-brain barrier delivery
US20070213264A1 (en) * 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
US20100278801A1 (en) 2007-10-16 2010-11-04 Shepard H Michael Compositions comprising optimized her1 and her3 multimers and methods of use thereof
WO2009114110A1 (en) * 2008-03-08 2009-09-17 Immungene, Inc. Engineered fusion molecules immunotherapy in cancer and inflammatory diseases
JP2011527579A (ja) * 2008-07-08 2011-11-04 アボット・ラボラトリーズ プロスタグランジンｅ２結合タンパク質およびこの使用
EP2808339B1 (en) 2008-11-28 2017-02-15 Zensun (Shanghai) Science & Technology, Co., Ltd. Neuregulin peptides and their use
CA2775573A1 (en) * 2009-10-09 2011-04-14 Merck Sharp & Dohme Corp. Generation, characterization and uses thereof of anti-her 3 antibodies
CN102139095A (zh) 2010-01-29 2011-08-03 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物
EP2555788B1 (en) * 2010-03-24 2017-10-11 Massachusetts Institute of Technology NEUREGULIN DIMER FOR AN ErbB/HER RECEPTOR FOR USE IN REDUCING CARDIOTOXICITY.
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
CN105849125B (zh) * 2013-11-07 2020-05-15 国家医疗保健研究所 神经调节蛋白变构抗her3抗体
CN110946993A (zh) 2014-01-03 2020-04-03 上海泽生科技开发股份有限公司 纽兰格林制剂的配方
TWI874262B (zh) * 2014-04-10 2025-02-21 日商第一三共股份有限公司 抗her3抗體-藥物結合物之用途
WO2016038609A1 (en) * 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Anti-her3 antibodies and uses of same
CN111407882A (zh) 2014-10-17 2020-07-14 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
KR102185867B1 (ko) 2016-02-06 2020-12-02 에피맙 바이오테라퓨틱스 인코포레이티드 Fabs-인-탠덤 면역글로불린 및 이의 용도
CA3033694C (en) 2016-09-15 2023-06-27 Universitat Stuttgart Antigen binding protein against her3
KR20210022542A (ko) 2018-04-11 2021-03-03 샐러브리스 바이오테라퓨틱스, 인크. 인간 뉴레귤린-1(nrg-1) 재조합 융합 단백질 조성물 및 이의 사용 방법

Also Published As

Publication number Publication date
WO2019200033A1 (en) 2019-10-17
US20210347841A1 (en) 2021-11-11
IL277790A (en) 2020-11-30
EP4361177A2 (en) 2024-05-01
JP2023134436A (ja) 2023-09-27
AU2023285793A1 (en) 2024-01-18
JP2021535727A (ja) 2021-12-23
IL322374A (en) 2025-09-01
TWI834654B (zh) 2024-03-11
EP3774859A1 (en) 2021-02-17
EA202092458A1 (ru) 2021-02-08
PH12020551648A1 (en) 2021-07-26
EP4361177A3 (en) 2024-08-14
PT3774859T (pt) 2024-05-27
MX2020010740A (es) 2021-01-20
TWI888027B (zh) 2025-06-21
US11718652B2 (en) 2023-08-08
FI3774859T3 (fi) 2024-05-24
SG11202009831UA (en) 2020-11-27
AU2023285793B2 (en) 2026-01-22
CN113166218A (zh) 2021-07-23
US20230322877A1 (en) 2023-10-12
BR112020020646A2 (pt) 2021-02-23
AU2019252262B2 (en) 2023-10-05
IL277790B2 (en) 2026-01-01
MY204230A (en) 2024-08-16
US20200010522A1 (en) 2020-01-09
KR20210022542A (ko) 2021-03-03
CA3096420A1 (en) 2019-10-17
US11046741B2 (en) 2021-06-29
JP2025072502A (ja) 2025-05-09
DK3774859T3 (da) 2024-05-27
EP3774859B1 (en) 2024-03-13
TW202426470A (zh) 2024-07-01
NZ768694A (en) 2024-10-25
CN118909141A (zh) 2024-11-08
IL277790B1 (en) 2025-09-01
JP7631420B2 (ja) 2025-02-18
CO2020012621A2 (es) 2020-12-21
PE20210111A1 (es) 2021-01-19
CL2020002621A1 (es) 2021-06-11
AU2019252262A1 (en) 2020-10-22
CN113166218B (zh) 2024-08-13
ES2980163T3 (es) 2024-09-30
PL3774859T3 (pl) 2024-10-14
JP7575272B2 (ja) 2024-10-29
HUE066892T2 (hu) 2024-09-28
TW201945389A (zh) 2019-12-01

Similar Documents

Publication Publication Date Title
MX2025002112A (es) Composiciones de proteina de fusion recombinante neuregulina-1 (nrg-1) humana y metodos para su uso
EP4623992A3 (en) Antibodies specifically binding to human il-1r7
RU2015130100A (ru) TNF-альфа антиген-связывающие белки
MX2022005850A (es) Inmunoglobulinas modificadas para seleccionar depositos de amiloide como objetivo.
JP2018531914A5 (es)
JP2016529229A5 (es)
MX2020007024A (es) Sialidasas humanas recombinantes, proteinas de fusion de sialidasa y metodos para usar las mismas.
AR106991A1 (es) Anticuerpos neutralizantes del virus de inmunodeficiencia humana
EA202190138A1 (ru) Анти-sirp-бета1 антитела и способы их использования
AR108663A1 (es) ANTICUERPOS CONTRA a-SINUCLEÍNA Y SUS USOS
MX2021008207A (es) Proteínas de fusión multifuncionales y usos de las mismas.
EA200700136A1 (ru) Анти-cd154-антитела
EA202190378A1 (ru) Антитела против ifnar1 для лечения аутоиммунных заболеваний
JP2019510739A5 (es)
JP2017515473A5 (es)
BR112021020777A2 (pt) Vacina de subunidade do csfv
WO2017191327A3 (en) Her-2 binding antibodies
KR20180072819A (ko) Il-23에 대한 폴리펩티드
JP2018537117A5 (es)
WO2023141176A3 (en) Neutralizing antibodies and antigen-binding fragments thereof against omicron and other coronavirus variants, and methods of making and using the same
EA202192865A1 (ru) Лечение головной боли с использованием антител к cgrp
NZ768694B2 (en) Human neuregulin-1 (nrg-1) recombinant fusion protein compositions and methods of use thereof
MX2022005595A (es) Método para tratar o mejorar el síndrome de cushing usando proteínas de unión para el receptor peptídico inhibidor gástrico (gipr).
MX2022002293A (es) Péptidos recombinantes inmunotolerantes similares a la elastina y métodos de uso.
UA89348C2 (ru) Изолированное моноклональное антитело, которое связывает клеточно-ассоциированный полипептид са 125/о772р